 CRANBURY, N.J., March 03, 2021 GLOBE NEWSWIRE -- PMV Pharmaceuticals, Inc. Nasdaq: PMVP, a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided corporate highlights. 